-+ 0.00%
-+ 0.00%
-+ 0.00%

Caris Life Sciences Unveils the Next Evolution of Liquid Biopsy with Enhanced Caris Assure

Barchart·09/29/2026 05:30:00
Listen to the news

Integrated DNA, RNA and Whole-Blood Analysis Provides Deeper Molecular Insights for Precision Oncology

IRVING, Texas, Sept. 29, 2026 /PRNewswire/ -- Caris Life Sciences® (Caris), a leading AI TechBio company, today unveiled the enhanced Caris Assure®, a new evolution of liquid biopsy. By integrating Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS) and whole-blood analysis (for true CHIP identification) into a single platform, the enhanced Caris Assure assay provides a more complete molecular profile from a single blood draw, delivering deeper insights to help guide precision oncology decisions.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.